Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Novel monoclonal treatments in severe asthma

Research output: Contribution to journalReviewResearchpeer-review

  1. Overweight in childhood and adolescence: Does it lead to airway hyperresponsiveness in adulthood?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Objective confirmation of asthma diagnosis improves medication adherence

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Stability of FeNO and airway hyperresponsiveness to mannitol in untreated asthmatics

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Are recreational SCUBA divers with asthma at increased risk?

    Research output: Contribution to journalReviewResearchpeer-review

  5. Bronchial provocation testing does not detect exercise-induced laryngeal obstruction

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Primary ciliary dyskinesia patients have the same P. aeruginosa clone in sinuses and lungs

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The risk of asthma is increased among women with polycystic ovary syndrome: a twin study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: To provide a general overview of the current biological treatments and discuss their potential anti-asthmatic effects.

DATA SOURCES: We reviewed articles in PubMed found using the search words "Asthma/therapy AND antibodies, monoclonal/therapeutic use AND cytokines."

STUDY SELECTIONS: Only articles published in English since 2000 were considered. The search identified 29 studies; 8 additional studies were found by hand search, generating 37 studies.

RESULTS: Of the 37 studies investigating biological treatments of asthma, 5 were on the effects of anti-IgE (omalizumab); 12 on anti-IL-5; 8 on anti-IL-13; 5 on anti-IL-4R-α; 3 on anti-IL-9; one on TNF-α; one on anti-IL-2R-α; one on TSLP (Thymic Stromal Lymphopoietin); and one on OX40L. Sample sizes ranged from 3 to 943 participants. Studies of therapies targeting IgE, IL-2, IL4R-α, IL-5, and IL-13 showed some efficacy, whereas those targeting TSLP, IL-9, and TNF-α lacked convincing effectiveness.

CONCLUSION: Research on the biological treatment of asthma shows promising results. While anti-IgE (omalizumab) has been used in the treatment of asthma for some years, anti-IL-5 has recently been approved for use. The efficacy of results of other large studies with a longer duration is needed to draw a firm conclusion. Such studies should not only focus on clinical outcomes, but also consider asthma-related quality of life. Knowledge on the asthma phenotypes and identification of biomarkers associated with these will be useful for physicians considering the right treatment for the asthma patient.

Original languageEnglish
JournalThe Journal of asthma : official journal of the Association for the Care of Asthma
Volume54
Issue number10
Pages (from-to)991-1011
Number of pages21
ISSN0277-0903
DOIs
Publication statusPublished - Nov 2017

    Research areas

  • Journal Article

ID: 50120042